Murphy Middleton Hinkle & Parker Inc. Takes $556,000 Position in Sanofi $SNY

Murphy Middleton Hinkle & Parker Inc. bought a new position in shares of Sanofi (NASDAQ:SNY) during the fourth quarter, according to its most recent filing with the SEC. The fund bought 11,475 shares of the company’s stock, valued at approximately $556,000.

Several other institutional investors also recently added to or reduced their stakes in the stock. Financial Consulate Inc. purchased a new stake in Sanofi during the third quarter worth about $26,000. Measured Wealth Private Client Group LLC bought a new stake in Sanofi in the third quarter worth about $29,000. Palisade Asset Management LLC purchased a new position in Sanofi in the third quarter valued at about $30,000. First Horizon Corp bought a new position in shares of Sanofi during the 3rd quarter valued at approximately $33,000. Finally, Salomon & Ludwin LLC grew its position in shares of Sanofi by 1,046.3% during the 3rd quarter. Salomon & Ludwin LLC now owns 768 shares of the company’s stock valued at $39,000 after acquiring an additional 701 shares during the period. Institutional investors own 14.03% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on SNY shares. TD Cowen reaffirmed a “hold” rating on shares of Sanofi in a report on Tuesday, December 30th. Weiss Ratings reissued a “hold (c)” rating on shares of Sanofi in a report on Monday, December 29th. Guggenheim downgraded Sanofi from a “buy” rating to a “neutral” rating in a research report on Tuesday, December 9th. JPMorgan Chase & Co. restated a “neutral” rating on shares of Sanofi in a research note on Monday, December 8th. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating on shares of Sanofi in a research report on Friday, January 16th. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and eight have assigned a Hold rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $61.50.

Sanofi Stock Performance

Shares of SNY stock opened at $44.77 on Tuesday. The stock has a market capitalization of $109.19 billion, a P/E ratio of 12.44, a PEG ratio of 1.15 and a beta of 0.45. The company has a current ratio of 1.09, a quick ratio of 0.73 and a debt-to-equity ratio of 0.20. The firm’s 50 day moving average is $46.40 and its 200 day moving average is $48.02. Sanofi has a 12 month low of $43.32 and a 12 month high of $56.93.

Sanofi Profile

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.